Risk-based fraud detection: How centralized monitoring can boost data quality
HiRO and CluePoints Partnership Offers Market-Leading RBQM Opportunities in China
CluePoints Wins Scrip Award for Clinical Advance of the Year 2021
CluePoints SVP of Business Development to Speak at Clinical Trials Europe
CluePoints Chief Scientific Officer to Speak at CNS Summit Next Month
CluePoints Shortlisted for Multiple Awards in Recognition of Pioneering Risk-Based Quality Management Solution
CluePoints Chief Scientific Officer and Pfizer’s Global RBM Program Lead to Speak at #CQOF2021
Will ICH E6 (R3) Unleash the Potential of Risk-Based Trials?
CluePoints Partners with ZS to Provide Best-in-Class RBQM Expertise and Technology, Increasing Clinical Trial Efficiency and Improving Patient Outcomes
Find out where we’re headed next.
ICH E6 (R2)
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
ICH E6 (R2)
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.